Recent Updates
Recently added Catalysts
SPRB Positive Sentiment Score: 75/100

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Monday, July 27, 2026 1 min read
Key Takeaway: Spruce Biosciences has appointed Dr. Adrian Quartel as Chief Medical Officer. With over 25 years of experience in the pharmaceutical industry, Dr. Quartel is expected to lead the company's efforts in developing therapies for neurological disorders. This strategic appointment aligns with Spruce's mission to address significant unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a highly experienced CMO
  • Dr. Quartel has over 25 years in the pharmaceutical industry
  • Focus on developing therapies for neurological disorders

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior r

Frequently Asked Questions

Who has been appointed as the new CMO of Spruce Biosciences?

Dr. Adrian Quartel has been appointed as the Chief Medical Officer.

What is Dr. Quartel's experience in the pharmaceutical industry?

Dr. Quartel brings over 25 years of experience in the international pharmaceutical industry.

What is the focus of Spruce Biosciences?

Spruce Biosciences focuses on developing therapies for neurological disorders.

When did Dr. Quartel's appointment take effect?

Dr. Quartel's appointment as CMO is effective immediately.

Tags: SPRB Viatris Investor Conferences Healthcare Spruce Biosciences Adrian Quartel neurological disorders biopharmaceutical CMO appointment
Last updated: Jul 27, 2026

Biotech snapshot

Cash runway
$54M liquidity · $3M/mo burn
~16 mo
Low dilution risk
Lead asset
SPR001Phase 2
Congenital Adrenal Hyperplasia →

Catalyst track record

+42%
best trade around SPRB's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for SPRB.

See every catalyst's timing & PoA →